M&A Deal Summary

Alcon Acquires Ivantis

On November 8, 2021, Alcon acquired medical products company Ivantis for 475M USD

Acquisition Highlights
  • This is Alcon’s 7th transaction in the Medical Products sector.
  • This is Alcon’s 3rd largest (disclosed) transaction.
  • This is Alcon’s 7th transaction in the United States.
  • This is Alcon’s 5th transaction in California.

M&A Deal Summary

Date 2021-11-08
Target Ivantis
Sector Medical Products
Buyer(s) Alcon
Deal Type Add-on Acquisition
Deal Value 475M USD

Target

Ivantis

Irvine, California, United States
Ivantis is a designer, developer and commercialize of new technologies to treat eye disease. Ivantis was founded in 2007 and is based in Irvine, California.

Search 214,877 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Alcon

Fort Worth, Texas, United States

Category Company
Founded 1945
Sector Medical Products
DESCRIPTION

Alcon, Inc. is an eye care company that researches, develops, manufactures and markets pharmaceuticals, surgical equipment and devices, contacts lens solutions and other vision care products that treat diseases, disorders and other conditions of the eye. Alcon is located in Fort Worth, Texas and was formed in 1945.


DEAL STATS #
Overall 9 of 13
Sector: Medical Products M&A 7 of 9
Type: Add-on Acquisition M&A Deals 8 of 11
State: California M&A 5 of 6
Country: United States M&A 7 of 11
Year: 2021 M&A 1 of 1
Size (of disclosed) 3 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-03-18 PowerVision

Belmont, California, United States

PowerVision is a medical device development company focused on creating fluid-based intraocular lens implants. PowerVision’s unique lens design utilizes the eye's natural accommodating response to transport fluid in the intraocular lens which is implanted in the eye's capsular bag. PowerVision was founded in 2002 and is based in Belmont, California.

Buy $285M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-05-23 Kala Pharmaceuticals - EYSUVIS & INVELTYS

Watertown, Massachusetts, United States

Kala Pharmaceuticals' EYSUVIS & INVELTYS provides loteprednol etabonate suspension) 0.25% pharmaceutical eye drops and loteprednol etabonate suspension) 1%, the only corticosteroid for twice-a-day treatment of post-operative inflammation and pain following ocular surgery.

Buy $60M